Non Hodgkin Lymphoma Clinical Trial
Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma
Part 1: To characterize the safety profile of acalabrutinib alone or in combination with rituximab in subjects with R/R FL.
Part 2: To characterize the activity of acalabrutinib alone or in combination with rituximab in subjects with R/R MZL, as measured by ORR.
Part 3: To characterize the safety of acalabrutinib in combination with rituximab and lenalidomide in subjects with R/R FL
An Open-label, Phase 1b/2 Study of Acalabrutinib Alone or in Combination Therapy in Subjects with B-cell Non-Hodgkin Lymphoma
Men and women ≥ 18 years of age.
Part 1: A confirmed diagnosis of FL Grade 1, 2, or 3a, which has relapsed after, or been refractory to ≥ 1 prior therapy for FL, or subjects who have not previously received systemic anticancer therapy for FL., and which requires treatment.
Part 2: For subject with relapsed or refractory MZL:
Histologically confirmed MZL including splenic, nodal, and extranodal sub-types
Subjects with splenic MZL must have an additional measurable lesion, nodal or extranodal, as described in inclusion criterion #4;
Subjects with gastric mucosa-associated lymphoid tissue (MALT) lymphoma must be Helicobacter pylori (HP)-negative
Part 3: For subjects with FL: Pathologically confirmed diagnosis of FL Grade 1, 2, or 3a, which has relapsed after, or been refractory to ≥ 1 prior therapy for FL and which requires treatment per National Cancer Institute or ESMO clinical practice guidelines.
Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2.
Agreement to use contraception during the study and for 30 days after the last dose of study drugs if sexually active and able to bear or beget children.
•A life-threatening illness, medical condition or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety, interfere with the absorption or metabolism of acalabrutinib, or put the study outcomes at undue risk
Significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of screening, or any Class 3 or 4 cardiac disease as defined by the New York Heart Association Functional Classification, or Qtc >480 msec
Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel, gastric bypass, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction.
Breast feeding or pregnant
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 32 Locations for this study
Tucson Arizona, 85719, United States
Downey California, 90241, United States
Duarte California, 91010, United States
Fountain Valley California, 92708, United States
Santa Monica California, 90404, United States
Coral Gables FL Florida, 33146, United States
Chicago Illinois, 60611, United States
Chicago Illinois, 60612, United States
Chicago Illinois, 60637, United States
Louisville Kentucky, 40207, United States
New Orleans Louisiana, 70112, United States
Ann Arbor Michigan, 48109, United States
Morristown New Jersey, 07960, United States
Hawthorne New York, 10532, United States
Lake Success New York, 11042, United States
New York New York, 10021, United States
Syracuse New York, 13210, United States
Columbus Ohio, 43210, United States
Greenville South Carolina, 29615, United States
Dallas Texas, 75235, United States
Houston Texas, 77030, United States
San Antonio Texas, 78217, United States
Temple Texas, 76508, United States
Salt Lake City Utah, 84112, United States
Spokane Washington, 99208, United States
Waukesha Wisconsin, 53188, United States
Edmonton Alberta, t6G1Z, Canada
London Ontario, N6A 5, Canada
Toronto Ontario, M5G 2, Canada
Bologna , 40138, Italy
Milano , 20132, Italy
Palermo , 90146, Italy
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.